Formation Bio detailed its AI‑native drug development model and growth strategy, with CTO Dan Neil explaining how the company applies data, software and clinical execution to accelerate assets rather than sell platform services. Formation has raised more than $600 million and emphasizes a hub‑and‑spoke approach: in‑license or acquire promising assets, then apply integrated AI and operational tools to improve trial design and execution. The firm argues that clinical development is the near‑term area where AI delivers the greatest leverage. The company’s model and capital scale position it as a case study for platform‑enabled biopharma, and industry observers will watch how platform efficiencies translate into clinical and regulatory success.